Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CCR5 | P51681 | 6/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LGMN | Q99538 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4207412 | 0.84 | NPY5R (0.39) | KMT2ANPY5RMEN1POLBCCR5 | |
| SCHEMBL4212577 | 0.79 | OPRM1 (0.53) | CCR5OPRM1KCNH2 | |
| SCHEMBL4218106 | 0.77 | NPY5R (0.40) | KMT2ANPY5RMEN1POLBCCR5 | |
| SCHEMBL4210755 | 0.75 | MEN1 (0.36) | KMT2ANPY5RMEN1CCR5OPRM1 | |
| SCHEMBL4210620 | 0.75 | POLB (0.41) | KMT2ANPY5RMEN1POLBOPRM1 | |
| SCHEMBL4199545 | 0.74 | NPY5R (0.40) | KMT2ANPY5RMEN1POLBCCR5 | |
| SCHEMBL4205933 | 0.74 | CHRM1 (0.39) | ALDH1A1KCNH2 | |
| SCHEMBL4217148 | 0.71 | CCR5 (0.39) | KMT2ANPY5RMEN1CCR5KDM4E | |
| SCHEMBL10653491 | 0.70 | OPRM1 (0.42) | KMT2AMEN1OPRM1CASP1CASP7 | |
| Hydrochloric Acid SCHEMBL10655291 | 0.69 | OPRM1 (0.41) | KMT2AMEN1OPRM1CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488738-B2 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-6998401-B2 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | SUNTORY LIMITED (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050245574-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1045693-B1 | AMINOPHENOXYACETIC ACID DERIVATIVES AS NEUROPROTECTANTS | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-06-30 | — | — | EP | disclosed |
| US-20040063748-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| US-6559146-B1 | Neuroprotective effects by inducing calbindin D28Kd, one of Ca2+-binding proteins | SUNTORY LIMITED (JP) | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245574-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | CAMK2A, CAMK2B, SLC1A2 | KMT2A 2011/4885NPY5R 113/4885MEN1 4652/4885 |
| US-20040063748-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | FABP7, SLC1A2, CAMK2A | KMT2A 2239/4885NPY5R 119/4885MEN1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.